Captrust Financial Advisors Mersana Therapeutics, Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$2.84 - $5.0 $105 - $185	-37 Reduced 14.07%	226 $1,000
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $355 - $629	-95 Reduced 26.54%	263 $1,000
Q4 2021 Feb 14, 2022	SELL	$5.48 - $9.86 $383 - $690	-70 Reduced 16.36%	358 $2,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $24,067 - $41,689	-1,572 Reduced 78.6%	428 $7,000
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $33,680 - $55,180	2,000 New	2,000 $53,000

130

104M

58.5K

471K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $56.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.